Sulfonylureido Thiazoles as Fructose-1,6-Bisphosphatase Inhibitors for the Treatment of Type-2 Diabetes.
Kitas, E., Mohr, P., Kuhn, B., Wessel, H.P., Hebeisen, P., Haap, W., Ruf, A., Benz, J., Joseph, C., Huber, W., Alvarez Sanchez, R., Paehler, A., Bernadeau, A., Gubler, M., Schott, B., Tozzo, E.(2010) Bioorg Med Chem Lett 20: 594
- PubMed: 19969452 
- DOI: https://doi.org/10.1016/j.bmcl.2009.11.093
- Primary Citation of Related Structures:  
2WBB, 2WBD - PubMed Abstract: 
Sulfonylureido thiazoles were identified from a HTS campaign and optimized through a combination of structure-activity studies, X-ray crystallography and molecular modeling to yield potent inhibitors of fructose-1,6-bisphosphatase. Compound 12 showed favorable ADME properties, for example, F=70%, and a robust 32% glucose reduction in the acute db/db mouse model for Type-2 diabetes.
Organizational Affiliation: 
F. Hoffmann-La Roche Ltd, Discovery Research Basel, CH-4070 Basel, Switzerland. eric_a.kitas@roche.com